Author

Giovanna Bellotti

Institution: National Cancer Center

Observed institutions: National Cancer Center, Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo

OpenAlex ID: A5000629664

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

2024 · Nicoletta Colombo, Elena Biagioli, et al. · The Lancet Oncology · 136

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

2025 · Hani M. Babiker, Vincent Picozzi, et al. · Journal of Clinical Oncology · 48

Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer patient survival

2023 · Claudia Curcio, Tiziana Rosso, et al. · Clinical and Experimental Medicine · 6

Phase II randomized study of maintenance therapy with regorafenib (REGO) versus placebo after first-line platinum and fluoropyrimidines-based chemotherapy in HER2 negative locally advanced/metastatic gastric (GC) or gastroesophageal junction (GEJ) cancer: Results of a-MANTRA study (GOIRC-05-2016).

2024 · Angela Damato, Domenico Bilancia, et al. · Journal of Clinical Oncology · 1

Impact of Osteonecrosis of Jaw (ONJ) on ten year experience of a multidisciplinary osteoncology team.

2021 · Vittorio Fusco, Antonella Fasciolo, et al. · 1

Works count: 5

Citation count: 192

H-index: 3

I10-index: 2